Mounjaro vs Zepbound: Which GLP-1 Is Better?

Bold opening

Mounjaro (tirzepatide) and Zepbound (also tirzepatide) are the same medication—just branded differently. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved for chronic weight management in adults with obesity or overweight with weight-related conditions. Both contain tirzepatide, a dual-action GLP-1 and GIP receptor agonist, making them more effective than single-mechanism GLP-1 drugs like semaglutide. However, differences in dosing, insurance coverage, and patient eligibility mean one may suit you better than the other. Below, we break down the key comparisons to help you decide.

Mounjaro vs Zepbound for Weight Loss

Both Mounjaro and Zepbound deliver identical weight loss results because they contain the same active ingredient, tirzepatide. In the SURMOUNT-1 trial, participants taking the highest dose (15 mg) lost an average of 20.9% of their body weight over 72 weeks—far surpassing older GLP-1 medications like semaglutide (Wegovy), which averages 15% weight loss. Mounjaro, initially approved for diabetes, was later found to produce significant weight loss, leading to Zepbound’s approval for obesity.

The key difference lies in accessibility. Mounjaro is prescribed off-label for weight loss, while Zepbound is explicitly approved for obesity. However, since they’re the same drug, weight loss outcomes are identical. Some patients start with Mounjaro (if they have diabetes) and transition to Zepbound later. For those without diabetes, Zepbound may be easier to obtain with insurance coverage for weight management.

Side Effects Compared

Since Mounjaro and Zepbound are the same medication, their side effect profiles are nearly identical. The most common adverse effects include:

• Gastrointestinal issues: Nausea (18-22%), diarrhea (12-17%), constipation (6-10%), and vomiting (6-8%). These tend to be dose-dependent and improve over time.
• Hypoglycemia: Rare in non-diabetics but possible in those on insulin or sulfonylureas.
• Injection-site reactions: Mild redness or itching.
• Rare but serious risks: Pancreatitis, gallbladder disease, and (in animal studies) thyroid C-cell tumors (though human risk remains unclear).

A 2023 meta-analysis in JAMA found no significant difference in side effects between Mounjaro and Zepbound, as they’re the same drug. However, Mounjaro’s longer market presence means more real-world data on long-term tolerability. Patients should start at the lowest dose (2.5 mg) to minimize side effects before titrating up.

Cost: Mounjaro vs Zepbound

The cost of Mounjaro and Zepbound is nearly identical—around $1,000–$1,500 per month without insurance. However, coverage varies significantly:

• Mounjaro: Often covered for type 2 diabetes but may require prior authorization for weight loss (off-label use). Some insurers deny coverage unless the patient has diabetes.
• Zepbound: More likely to be covered for obesity (BMI ≥30 or ≥27 with weight-related conditions), but insurers may still impose strict criteria, such as documented failed weight loss attempts.

Manufacturer savings programs can reduce costs:

• Mounjaro: Eli Lilly offers a $25 copay card for commercially insured patients (up to $150/month for 12 months).
• Zepbound: A similar $25 copay card is available, but eligibility may differ.

For uninsured patients, Mounjaro and Zepbound are equally expensive, though some pharmacies offer discounts. Always check with your insurer to compare out-of-pocket costs.

How They Work Differently

Mounjaro and Zepbound are dual GLP-1 and GIP receptor agonists, setting them apart from single-mechanism GLP-1 drugs like semaglutide (Ozempic/Wegovy). Here’s how they work:

1. GLP-1 (Glucagon-like peptide-1) effects:

   • Slows gastric emptying, reducing appetite.
   • Enhances insulin secretion in response to meals.
   • Suppresses glucagon (a hormone that raises blood sugar).

2. GIP (Glucose-dependent insulinotropic polypeptide) effects:

   • Further enhances insulin release.
   • May improve fat metabolism and reduce fat storage.

In head-to-head trials, Mounjaro (and thus Zepbound) led to greater weight loss and HbA1c reduction than semaglutide. A 2022 NEJM study found Mounjaro reduced HbA1c by 2.0–2.3% (vs. 1.9% for semaglutide) and weight by 12.4 kg (vs. 6.2 kg for semaglutide). Since Zepbound is the same drug, it achieves identical results.

Which Is Better?

The choice between Mounjaro and Zepbound depends on indication, insurance, and access, not efficacy. Here’s how to decide:

• For diabetes + weight loss: Mounjaro is the clear choice, as it’s FDA-approved for type 2 diabetes and often covered by insurance for this purpose.
• For obesity without diabetes: Zepbound is the better option, as it’s explicitly approved for weight management, making insurance approval more likely.
• Cost considerations: If your insurer covers Mounjaro for weight loss (off-label), it may be cheaper than Zepbound. However, Zepbound’s approval for obesity could improve coverage over time.

Since they’re the same drug, neither is “better”—it’s about which one your doctor can prescribe and your insurer will cover. Always discuss your goals (diabetes control vs. weight loss) with your provider.

Switching Between Mounjaro and Zepbound

Switching between Mounjaro and Zepbound is seamless because they’re the same medication. Here’s what to expect:

• From Mounjaro to Zepbound: If you’re using Mounjaro for weight loss (off-label) and Zepbound becomes available, your doctor can simply write a new prescription for Zepbound at the same dose. No titration is needed.
• From Zepbound to Mounjaro: If you lose insurance coverage for Zepbound but qualify for Mounjaro (e.g., if you develop diabetes), the switch is equally smooth. Your dose remains unchanged.

Key considerations:

• Insurance: Confirm coverage before switching. Some plans may reject Zepbound if you don’t meet obesity criteria, even if you’re already on Mounjaro.
• Side effects: Since the drug is identical, side effects won’t change. However, if you switch due to cost, ensure you can afford the new copay.
• Dosing: Both are available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pens. Your doctor will prescribe the same dose unless you’re adjusting for tolerability.

Insurance Coverage Compared

Insurance coverage is the biggest differentiator between Mounjaro and Zepbound. Here’s how it breaks down:

Tips to improve coverage:

• For Mounjaro: If using off-label for weight loss, your doctor may need to document failed weight loss attempts with diet/exercise.
• For Zepbound: Insurers often require a BMI ≥30 or ≥27 with conditions like hypertension or sleep apnea.
• Appeals: If denied, your doctor can submit a prior authorization appeal with clinical justification.

Frequently Asked Questions

Is Mounjaro or Zepbound better?

Neither is “better”—they’re the same drug. Mounjaro is ideal for diabetes, while Zepbound is optimized for obesity. The “better” choice depends on your medical needs and insurance coverage.

Can you switch from Mounjaro to Zepbound?

Yes, switching is simple since they’re identical. Your doctor can prescribe Zepbound at the same dose as Mounjaro, but check insurance coverage first to avoid unexpected costs.

Which has fewer side effects?

Both have identical side effects because they contain the same active ingredient. Nausea, diarrhea, and constipation are the most common, but these often improve with time and dose adjustments.

Disclaimer from Dr. Amanda Liu This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or switching medications like Mounjaro or Zepbound. Individual results may vary, and insurance coverage depends on your specific plan.